Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26;8(1):016111.
doi: 10.1063/5.0186642. eCollection 2024 Mar.

A multi-scale numerical approach to study monoclonal antibodies in solution

Affiliations

A multi-scale numerical approach to study monoclonal antibodies in solution

Marco Polimeni et al. APL Bioeng. .

Abstract

Developing efficient and robust computational models is essential to improve our understanding of protein solution behavior. This becomes particularly important to tackle the high-concentration regime. In this context, the main challenge is to put forward coarse-grained descriptions able to reduce the level of detail, while retaining key features and relevant information. In this work, we develop an efficient strategy that can be used to investigate and gain insight into monoclonal antibody solutions under different conditions. We use a multi-scale numerical approach, which connects information obtained at all-atom and amino-acid levels to bead models. The latter has the advantage of reproducing the properties of interest while being computationally much faster. Indeed, these models allow us to perform many-protein simulations with a large number of molecules. We can, thus, explore conditions not easily accessible with more detailed descriptions, perform effective comparisons with experimental data up to very high protein concentrations, and efficiently investigate protein-protein interactions and their role in phase behavior and protein self-assembly. Here, a particular emphasis is given to the effects of charges at different ionic strengths.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to disclose.

Figures

FIG. 1.
FIG. 1.
The experimental mAbs structure at atomic resolution (leftmost, gray) is first relaxed using MD simulations, where-after it is coarse-grained at five different levels shown in the middle, in red. This includes models with 1, 6, 9, or 12 interaction sites, as well as a model where each amino acid is treated as a (charged) sphere. The coarse-grained models are subsequently used in many-body MC simulations to explore the effect of varying mAb concentration and salt concentrations (rightmost).
FIG. 2.
FIG. 2.
Root mean squared deviation (RMSD) and radius of gyration (Rg) obtained from all-atom MD simulations for the condition I = 7 mM [(a) and (b)] and I = 57 mM [(c) and (d)]. The equilibrated part of the trajectory over which the average Rg is calculated is highlighted in red.
FIG. 3.
FIG. 3.
mAb structure before and after MD simulations. At the leftmost, the initial mAb structure at atomic resolution overlaps with its coarse-grained representation at the amino acid level. On the center and rightmost, the representative mAb conformations obtained from MD simulations, respectively, for the conditions at 7 and 57 mM of ionic strength. Red, blue, and gray beads represent negatively charged, positively charged, and neutral amino acids, respectively.
FIG. 4.
FIG. 4.
Effective structure factors, Seff(q), obtained from simulations of Np = 20 mAbs coarse-grained at an amino acid level in comparison with experimental data. The left and right columns refer to, respectively, the 7 and 57 mM ionic strength conditions, while on each graph the mAb concentration is indicated. The gray circles in the background represent the experimental data obtained by SAXS experiments together with their error bars, while the open symbols are the simulation results. Each of the colors indicates a different value of the depth of the attractive well in the Lennard–Jones term of Eq. (3), εij. The explored range is Δεij= 0.05–0.085  kBT with steps of 0.005  kBT.
FIG. 5.
FIG. 5.
Effective structure factors, Seff(q), obtained from simulations of Np = 20 mAbs coarse-grained at an amino acid level and at low ionic strength (7 mM). Comparison with initial and relaxed structure. The explored range is Δεij=0.050.085kBT with steps of 0.005  kBT for both cases.
FIG. 6.
FIG. 6.
χ2 table for the 1-bead (a), 6-bead (b), 9-bead (c), and 12-bead (d) models related to the condition at low mAb concentration (20 mg/mL) and low ionic strength (7 mM) for several combinations of the potential parameters (Qeff, εij). Each χ2 value is associated with a color. A logarithmic scale is used to highlight differences among the values which are rounded to two decimal places.
FIG. 7.
FIG. 7.
Effective structure factors, Seff(q), obtained from experimental data (gray circles) at low ionic strength (7 mM) and 20 mg/mL (left) and 150 mg/mL (right) mAb concentrations in comparison with the 1-bead model (dashed orange line) and an effective charge of Qeff = 20 e and the 6-bead model (open circles) and an effective charge in the range ΔQeff=26 ± 2e.
FIG. 8.
FIG. 8.
Values of Qeff best reproducing the experimental data for the different bead models used as judged from the -tables shown in Figs. 6 and S6–S9 in the supplementary material.
FIG. 9.
FIG. 9.
Effective structure factors Seff(q), obtained from simulations with the 9-bead model and an effective charge in the range of ΔQeff=2630e in comparison with experimental data (gray circles). Here, the attractive term is van der Waals-like with ϵij=0.8kBT.

Similar articles

Cited by

References

    1. Hafeez U., Gan H. K., and Scott A. M., “ Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases,” Curr. Opin. Pharmacol. 41, 114–121 (2018).10.1016/j.coph.2018.05.010 - DOI - PubMed
    1. Du F. H., Mills E. A., and Mao-Draayer Y., “ Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment,” Autoimmun. Highlights 8, 12 (2017).10.1007/s13317-017-0100-y - DOI - PMC - PubMed
    1. Pantaleo G., Correia B., Fenwick C., Joo V. S., and Perez L., “ Antibodies to combat viral infections: Development strategies and progress,” Nat. Rev. Drug Discovery 21, 676–696 (2022).10.1038/s41573-022-00495-3 - DOI - PMC - PubMed
    1. Mullard A., “ FDA approves 100th monoclonal antibody product,” Nat. Rev. Drug Discovery 20, 491–495 (2021).10.1038/d41573-021-00079-7 - DOI - PubMed
    1. Kollár É., Balázs B., Tari T., and Siró I., “ Development challenges of high concentration monoclonal antibody formulations,” Drug Discovery Today: Technol. 37, 31–40 (2020).10.1016/j.ddtec.2020.08.005 - DOI - PubMed